People who survive an episode of severe alcoholic hepatitis should be advised to maintain total abstinence from alcohol.

Stephen R Atkinson¹, Andrew McQuillin³, Marsha Y Morgan²*, Mark R Thursz¹*

*Joint senior authors

¹ Department of Hepatology, Division of Surgery and Cancer, Imperial College London, UK

stephen.atkinson@imperial.ac.uk; m.thursz@imperial.ac.uk

² UCL Institute for Liver & Digestive Health, Division of Medicine, Royal Free Campus, University College London, London, UK

marsha.morgan@ucl.ac.uk;

³ Molecular Psychiatry Laboratory, Division of Psychiatry, University College London, London, UK

a.mcquillin@ucl.ac.uk

Word count: 547 (including references)

Corresponding author:

Dr Stephen Atkinson
Department of Hepatology
10th Floor QEQM, St Marys’ Hospital
London W2 1NY, UK

Telephone: 020 3312 6454 Fax: 020 7724 9369

Email: stephen.atkinson@imperial.ac.uk

This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process which may lead to differences between this version and the Version of Record. Please cite this article as doi: 10.1002/hep.29825

This article is protected by copyright. All rights reserved.
Dear Sir,

We read with interest the article published in HEPATOLOGY by Louvet and colleagues (1) highlighting factors influencing outcomes in people with severe alcoholic hepatitis. They found that beyond six months, alcohol relapse, defined using a threshold of $\geq 30$ g/day, was an independent predictor of mortality with a dose-related effect on the hazard ratio (HR).

The effect of drinking behaviour on outcome has also been examined in data collected via the Steroids and Pentoxyfylline for Severe Alcoholic Hepatitis (STOPAH) trial (2). Patients were classified, in the original published analysis, as abstinent or drinking. A return to alcohol consumption at day 90 conferred significantly greater mortality at day 450 than abstinence (HR 2.77, 95% Confidence Intervals (CI) 1.79–4.29; $p<0.00001$). We have re-examined these data in an attempt to replicate the dose-dependent effect of drinking on mortality observed by Louvet and colleagues (1).

Participants enrolled in the STOPAH trial were treated for 28 days with prednisolone, pentoxifylline, both or placebo (3). Patients categorised their drinking behaviour at day 90 as (i) abstinent; or (ii) drinking daily at low levels: men $\leq 24$g; women $\leq 16$g; (iii) moderate levels: men $>24$ but $\leq 60$g; women $>16$ but $\leq 40$g; or (iv) high levels: men $>60$g; women $>40$g.

The association between drinking behaviour and survival was examined using Cox proportional hazards regression analysis (2).

Data on drinking behaviour were available in 397 patients; of these 84 (9.7%) died by day 450. A total of 138 (35%) had returned to drinking; the distribution within the three drinking categories was reasonably even. There was a clear dose-dependent increased in the HR as drinking levels increased viz: low 2.09 (95% CI 1.13–3.88, $p=0.02$), moderate 3.00 (95% CI 1.69–5.35, $p<0.001$) and high 3.31 (95% CI 1.86–5.90, $p<0.001$) (Figure 1).
Thus, while Louvet and colleagues (1) found a dose-related effect on the HR for death above \( \geq 30\text{g/day} \), we have shown that a return to drinking, \textit{at any level}, confers a dose-related increase in the risk of death. Our use of sex-specific drinking thresholds, based on our previous finding that sex is an independent risk factor for mortality in people with severe alcoholic hepatitis who return to drinking (2), contrasts with the French group’s use of a generic drinking threshold; this may explain the difference in our findings.

Whilst alcohol relapse is clearly detrimental, people who survive an episode of severe alcoholic hepatitis and subsequently attain and maintain abstinence from alcohol still exhibit an appreciable mortality. We have shown previously that homozygosity for rs738409:G in \textit{PNPLA3} is an independent risk factor for medium-term mortality in this population (2). Both this genetic variant and sex should be added to the risk factors identified by Louvet and colleagues as determinants of outcome in severe alcoholic hepatitis (1).
References


Keywords
alcohol dependence, alcoholic hepatitis, alcohol-related cirrhosis, PNPLA3; survival; mortality, liver-related; alcohol relapse

Financial support
NIHR HTA grant 08/14/44
University College London (Impact PhD fellowship award MJW)
Medical Research Council (UK) – Grant number MR/M003132/1
Imperial College BRC programme

Conflict of interest
The authors have no conflicts of interest to declare

Authors’ contribution
SRA performed statistical analyses and with MYM drafted and revised the manuscript. AQ, MYM and MRT recruited participants; all authors critically appraised the final manuscript.
Survival (percent)

Time since treatment start (days)

Level of alcohol consumption

- Abstinent
- Low
- Moderate
- High

Abstinent 259 257 238 227 221 212
Low 51 51 45 41 38 37
Moderate 44 44 40 38 32 27
High 43 42 34 32 28 24

Numbers at risk
Figure 1. Survival in patients with severe alcoholic hepatitis alive at 90 days, by subsequent drinking behaviour. Survival times, and mortality endpoints, were calculated with respect to the treatment start date or, if not recorded, the date of randomization; cases were censored at the time of liver transplantation, the limit of follow-up or day 450, whichever occurred first. Compared to abstinence a clear dose-dependent increase in the risk of mortality at day 450 is seen with low (HR 2.09, 95% CI 1.13 – 3.88, P=0.02), moderate (HR 3.00, 95% CI 1.69 – 5.35, P<0.001) and high-level alcohol relapse (HR 3.31, 95% CI 1.86 – 5.90, P<0.001).
Figure 1. Survival in patients with severe alcoholic hepatitis alive at 90 days, by subsequent drinking behaviour. Survival times, and mortality endpoints, were calculated with respect to the treatment start date or, if not recorded, the date of randomization; cases were censored at the time of liver transplantation, the limit of follow-up or day 450, whichever occurred first. Compared to abstinence a clear dose-dependent increase in the risk of mortality at day 450 is seen with low (HR 2.09, 95% CI 1.13 – 3.88, P=0.02), moderate (HR 3.00, 95% CI 1.69 – 5.35, P<0.001) and high-level alcohol relapse (HR 3.31, 95% CI 1.86 – 5.90, P<0.001).